Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 3 от 154

Само по покана

A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007

T-cell Acute Lymphoblastic Leukemia T-cell Lymphoblastic Lymphoma

This study will provide long-term follow-up for patients who have received treatment with WU-CART-007 in a previous clinical trial. In this study, patients will be followed for up to 15 years after their last dose of WU-CART-007 for evaluation of delayed adverse events, presence of persisting WU-CART-007 vector sequences, and overall survival and progression-free survival.

Начало: 22.08.2022 Край: 01.07.2037 Възраст: от 12 г.

Australia, United States Wugen, Inc. NCT05509855

Само по покана Фаза 2/3

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

Dermatitis Atopic

This is an open-label, Phase 2/Phase 3, long-term extension study for treatment of participants of previous amlitelimab clinical trials in moderate to severe atopic dermatitis. The purpose of this study is to characterize the safety and efficacy of amlitelimab in treated participants with moderate to severe atopic dermatitis (AD) who have previously been enrolled in an amlitelimab clinical trial. All participants will have visits during the treatment period every 4 weeks. Responder participants rolling over from EFC17599 and EFC17600, and responder participants enrolling through screening from DRI17366 will be initiated into drug withdrawal (with no drug administration) at LTS17367 baseline visit to monitor durability of treatment response. If these responder participants relapse during LTS17367, they will have treatment restored. Non-responder participants rolling over from EFC17599 or EFC17600, and non-responder participants enrolling through screening from DRI17366 will have treatment administration from LTS17367 baseline. Participants rolling over from DRI17366, SFY17915 and INT18404 will also have treatment administration from LTS17367 baseline. Remote visits with home dosing are allowed for the purpose of study drug administration, when applicable. In the case of remote visit with home dosing, the participant or a caregiver may administer study drug after appropriate training. Alternatively, if needed, and based on the investigator's judgement, home visits with healthcare professional assistance or on-site study drug administration visits can be performed. Where participants discontinue amlitelimab permanently during LTS17367, safety follow up will be performed for a minimum of 140 days from the last amlitelimab administration.

Начало: 22.08.2022 Край: 22.01.2029 Възраст: от 12 г. Лечение

Argentina, Australia, Brazil +24 Sanofi NCT05492578

Само по покана Фаза 2

ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study

Age Related Macular Degeneration (AMD)

The purpose of this study is to evaluate the long-term safety of GT005 in participants with Geographic Atrophy (GA) secondary to AMD who have been treated in an antecedent study.

Начало: 12.07.2022 Край: 02.06.2028 Възраст: от 55 г. Друго

Australia, France, Germany +3 Gyroscope Therapeutics Limited NCT05481827

Само по покана Фаза 3

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia

Biliary Atresia

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia

Начало: 05.07.2022 Край: 31.08.2028 Лечение

Australia, Canada, China +11 Albireo, an Ipsen Company NCT05426733

Само по покана

A Comparison of Metacarpophalangeal Joint Blocking Splint With Relative Motion Extension Splint for Trigger Finger

Trigger Finger

The purpose of this research is to evaluate the effectiveness of two splint designs in conservative management of trigger finger.

Начало: 01.03.2022 Край: 31.03.2028 Лечение

New Zealand Waikato Hospital NCT06137404

Само по покана

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Solid and Hematological Malignancies

The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-363, KITE-753, KITE-197, and anitocabtagene autoleucel in participants of Kite-sponsored interventional studies.

Начало: 15.12.2021 Край: 01.12.2040

Australia, Belgium, Canada +10 Kite, A Gilead Company NCT05041309

Само по покана

Longitudinal Study of a Bionic Eye

Retinitis Pigmentosa Choroideremia

This is a longitudinal observational study with participants who have been implanted with the suprachoroidal retinal prosthesis.

Начало: 09.12.2021 Край: 09.12.2026

Australia Center for Eye Research Australia NCT05158049

Само по покана Фаза 2

Extension Study of Infigratinib in Children With Achondroplasia (ACH)

Achondroplasia

This is a Phase 2, multicenter, open-label, extension (OLE) study to evaluate the long-term safety, tolerability, and efficacy of infigratinib, an FGFR 1-3-selective tyrosine kinase inhibitor, in subjects with ACH who previously completed a QED-sponsored interventional study, and potentially in additional subjects who are naïve to infigratinib treatment. Quality of Life assessments for this subject population will also be evaluated. Treatment-naïve subjects must have at least a 6-month period of growth assessment in study QBGJ398-001 (PROPEL) and will be enrolled in this OLE study only after a dose to be explored further is identified in Phase 2 Study QBGJ398-201 and subjects are not otherwise eligible to enroll in another QED-sponsored Phase 2 or Phase 3 ACH study.

Начало: 06.12.2021 Край: 01.02.2032 Възраст: 3–18 г. Лечение

Argentina, Australia, Canada +7 QED Therapeutics, a BridgeBio company NCT05145010

Само по покана

Long-Term Follow-up of Subjects Who Were Treated With ST-920

Fabry Disease Fabry Disease, Cardiac Variant

Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 5 years following ST-920 infusion.

Начало: 16.08.2021 Край: 01.03.2039 Възраст: от 18 г.

Australia, Canada, Germany +2 Sangamo Therapeutics NCT05039866

Само по покана Фаза 3

Selatogrel Outcome Study in Suspected Acute Myocardial Infarction

Acute Myocardial Infarction

This study will randomize patients recently discharged from the hospital with a confirmed diagnosis of type 1 acute myocardial infarction (Thygesen et al. 2018) and having additional cardiovascular risk factors.

Начало: 14.08.2021 Край: 01.12.2026 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +33 Viatris Innovation GmbH NCT04957719

Само по покана

Distal Evaluation of Functional Performance with Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting

Coronary Artery Disease Ischemic Heart Disease

Multi-center, prospective, randomized controlled study comparing PCI guided by angiography versus iFR Co-Registration using commercially available Philips pressure guidewires and the SyncVision co-registration system, employing an adaptive design study for interim sample size re-estimation.

Начало: 17.06.2021 Край: 01.06.2028 Възраст: от 18 г. Лечение

Australia, Canada, Denmark +11 Philips Clinical & Medical Affairs Global NCT04451044

Само по покана Фаза 2/3

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

Symptomatic Hypertrophic Cardiomyopathy (HCM)

The purpose of this study is to collect long-term safety and tolerability data for aficamten.

Начало: 06.05.2021 Край: 01.03.2028 Възраст: 18–85 г. Лечение

Argentina, Australia, Brazil +14 Cytokinetics NCT04848506

Само по покана

Relationship Between Oral DMT Burden and Adherence in MS

Multiple Sclerosis Adherence, Medication

STATURE is a prospective observational six-arm translation multi-site study that will run for approx. 4.5 years. The primary aim is to measure treatment burden and its relationship to medication adherence across six self-administered oral disease-modifying therapies (cladribine, dimethyl fumarate, fingolimod, teriflunomide, ozanimod, and diroximel fumarate) in multiple sclerosis (MS). The information gained will assist prescribing decision-making; accounting for medication burden at a patient level and potential implications on medication adherence and persistence, thus minimising primary and secondary healthcare costs. Three-hundred and twenty-three individuals with MS will be recruited into the study. Patient-reported outcome measures will be administered via Qualtrics, a secure online data collection tool. Medicare and pharmaceutical benefits scheme (PBS) data will also be collected.

Начало: 25.09.2020 Край: 11.07.2026 Възраст: 18–99 г.

Australia Monash University NCT04676204

Само по покана

Effects of Class III Elastics on Stability of Orthopaedic Class III Correction

Class III Malocclusion Underbite

The purpose of this study is to evaluate the effects of adding elastics to orthodontic retainers on the stability of class III correction and whether it reduces the need for jaw surgery.

Начало: 22.07.2020 Край: 01.01.2027 Възраст: 12–16 г. Превенция

Australia Sydney Local Health District NCT04911400

Само по покана

The TEAM Long-Term Cohort Study (A Sub-study of TEAM(III))

Critically Ill Mechanical Ventilation Long Term Outcome

This study is a prospective cohort study to evaluate the long-term effects of early activity and mobilisation compared to standard care on disability, function and health status for patients at 1, 2 and 5 years after recruitment of patients randomised into the TEAM Phase III RCT (ClinicalTrials.gov NCT03133377). The primary outcome of the study will be the level of disability as measured by the World Health Organisation's Disability Schedule 2.0, 12 level (WHODAS) at 2 years after recruitment.

Начало: 11.02.2020 Край: 01.11.2026 Възраст: от 18 г.

Australia Australian and New Zealand Intensive Care Research Cent NCT05298982

Само по покана Фаза 3

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Warm Antibody Autoimmune Hemolytic Anemia

The primary objective of this study is: • To evaluate the long-term safety of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA).

Начало: 30.10.2019 Край: 01.04.2024 Възраст: 18–100 г. Лечение

Australia, Belarus, Bulgaria +13 Rigel Pharmaceuticals NCT04138927

Само по покана Фаза 3

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

PAH Pulmonary Hypertension Pulmonary Arterial Hypertension Hypertension +7

Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.

Начало: 23.09.2019 Край: 01.12.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +27 United Therapeutics NCT03683186

Само по покана

Zoledronate In the Prevention of Paget's Disease: Long Term Extension

Paget Disease

Paget's disease of the bone (PDB) is a metabolic bone disorder which in some individuals can cause pain, bone deformity, arthritis and deafness, although in many patients it does not cause symptoms. Paget's disease has a strong genetic component and SQSTM1 is the most important susceptibility gene. People who inherit mutations in SQSTM1 have a high risk of developing PDB later in life. This study is an extension of the ZiPP (Zoledronate in the Prevention of Paget's) study which was is randomised trial currently in progress to determine if the bisphosphonate zoledronic acid (ZA) can prevent or delay the development of PDB-like bone lesions compared with a dummy treatment (placebo) in people who inherit SQSMT1 gene mutations. Although the ZiPP study will provide information on whether early ZA treatment can favourably influence bone lesion development the significance of this to the patient in terms of symptoms is unclear as yet. The aim of the extension study is to keep these individuals under surveillance for any symptoms or signs of PDB over a further 5 year period and to evaluate if there has been any progression of PDB-like lesions by bone scan at the end of this period.

Начало: 05.04.2019 Край: 01.05.2027

Australia, Belgium, Ireland +4 University of Edinburgh NCT03859895

Само по покана Фаза 2/3

Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS

Fragile X Syndrome

ZYN002 is a pharmaceutically manufactured Cannabidiol that is developed as a clear gel that can be applied to the skin (called transdermal delivery). The gel will be applied to clean, dry, intact skin of the shoulders and/or upper arms. Participants from the ZYN2-CL-016 and ZYN2-CL-033 studies who meet the inclusion criteria and none of the exclusion criteria for study ZYN2-CL-017 are eligible. Parents/caregivers will apply the study gel twice daily for the 52-week treatment period.

Начало: 09.11.2018 Край: 31.08.2027 Възраст: 3–29 г. Лечение

Australia, New Zealand, United Kingdom +1 Zynerba Pharmaceuticals, Inc. NCT03802799

Само по покана

International Registry of Congenital Portosystemic Shunt (IRCPSS)

Congenital Portosystemic Shunt CPSS (Congenital Portosystemic Shunt)

Congenital Portosystemic Shunt (CPSS) is a rare condition important by the multiplicity and severity of associated complications. CPSS is venous anomaly in which blood coming from the intestines only partially passes through the liver. This leads to the accumulation of potentially toxic factors that cause systemic effects. Complications vary among the individuals, and currently, it is challenging to predict which individuals will develop severe complications. The IRCPSS registry is established with the aim of centralizing detailed clinical follow-up and biological information from participants around the world who suffer from Congenital Portosystemic Shunt (CPSS). A multidisciplinary consortium of experts is collaborating to enhance our understanding of the prevalence, natural history, individual risks, and physiopathology of the disease through the IRCPSS registry.

Начало: 26.04.2018 Край: 31.12.2028 Възраст: от 1 г.

Australia, Belgium, Canada +13 Prof. Valérie Mc Lin NCT06041906

1 2 3 4 5 … 154